ClinicalTrials.gg
Sign In
CompletedNCT00000354Updated Jan 12, 2017

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3

A Phase 1 interventional study of Lofexidine in Opioid-Related Disorders and Substance-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to participants aged 21 Years to 59 Years. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by National Institute on Drug Abuse (NIDA) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
0
Ages
21 Years to 59 Years
Sex
All
01

Study summary

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

02

Conditions studied

  • Opioid-Related Disorders
  • Substance-Related Disorders

Keywords

  • opiate dependence
03

In context

Opioid-Related Disorders

1,439 studies on the registry are indexed under Opioid-Related Disorders; 291 are open to participants now.

Browse Opioid-Related Disorders studies →

Lead sponsor

National Institute on Drug Abuse (NIDA) is the lead sponsor of 393 studies on the registry; 19 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.

Browse National Institute on Drug Abuse (NIDA) studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Please contact site for information.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Enrollment
0 participants

Interventions

06

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104 6178, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 1996, a primary completion of Sep 1997 and a completion of Dec 1997. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 1999
First posted
Sep 21, 1999
Start
Jul 1996
Primary completionActual
Sep 1997
CompletionActual
Dec 1997
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00000354
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of Pennsylvania
First posted
Sep 21, 1999
Start date
Jul 1996
Primary completion
Sep 1997
Completion
Dec 1997
Last update
Jan 12, 2017

Study contacts

Charles O'Brien, M.D., Ph.D.
principal investigator · PDVAMC Treatment Research Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lofexidine

Other studies in this condition

Opioid-Related Disorders →

Other studies from this sponsor

National Institute on Drug Abuse (NIDA) →

Start the discussion